Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

Key Inclusion Criteria:

- Willing and able to provide written informed consent

- Infection with HCV genotype 1

- HCV RNA > LLOQ at screening

- Participation in a prior Gilead-sponsored study

- Screening laboratory values within defined thresholds

- Use of two effective contraception methods if female of childbearing potential or
sexually active male

- Must be of generally good health, with the exception of chronic HCV infection, as
determined by the Investigator

- Must be able to comply with the dosing instructions for study drug administration and
able to complete the study schedule of assessments

Key Exclusion Criteria:

- Pregnant or nursing female or male with pregnant female partner

- Co-infection with HIV or hepatitis B virus (HBV)

- Current or prior history of clinical hepatic decompensation (Groups 1 and 2 only)

- Hepatocellular carcinoma (HCC)

- History of clinically significant illness or any other medical disorder that may
interfere with subject treatment, assessment or compliance with the protocol

Note: Other protocol defined Inclusion/Exclusion criteria may apply.